TEPEZZA® (teprotumumab-trbw) TED Treatment | HCP Home

Give your patients with Thyroid Eye Disease the keys to doing more of what they love1,2

 

TEPEZZA has been shown to reduce proptosis and improve diplopia in TED patients.1,*

 

*In clinical studies of 171 patients with TED. 1

The real impact of TED goes beyond the eyes

Visible and nonvisible signs and symptoms of TED can have a debilitating impact on your patients’ daily activities and self-confidence3-5

UNDERSTAND PATIENT BURDEN
The real impact of TED goes beyond the eyes

Benefits of TEPEZZA go beyond proptosis reduction1,2,6-9

 

In clinical studies:

 

  • Reduced proptosis1
  • Improved diplopia1,6

TEPEZZA was also studied for impact on:

 

  • Inflammation7
  • Patient-reported ability to perform daily activities2,8,9
SEE THE RESULTS
The real impact of TED goes beyond the eyes

Nearly 25,000 patients treated nationwide10,†

 

TEPEZZA has been studied in 4 published clinical trials with ~5 years of real-world experience2,8,9,11

See Real Results

†Based on 24,132 individual patients enrolled in Amgen By Your Side who received at least one dose of TEPEZZA from 02/05/2020 - 08/23/2025. TED diagnosis is assumed based on initiation of TEPEZZA.

Help get your patient started on TEPEZZA

Complete the Patient Enrollment Form to get your patient started on TEPEZZA

ENROLL YOUR PATIENTS NOW
co-pay
Patients with commercial insurance may be eligible for a $0 co-pay for the cost of the medication and the infusion administration through our Amgen Commercial Co-Pay Program*
*Subject to terms and conditions.
ACCESS COVERAGE SUPPORT

Hear how TEPEZZA
has changed the way
Dr Kimberly Cockerham treats TED

Hi I’m Kimberly Cockerham and I’m a board-certified ophthalmologist with sub-specialty training in orbit, plastics and neuro-ophthalmology.

TEPEZZA (teprotumumab-trbw) is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. TEPEZZA may cause infusion reactions. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion.

Please listen to additional Important Safety Information later in this video.

Thyroid eye disease is a chronic disorder.

Prior to January of 2020 when TEPEZZA was FDA approved as the first targeted treatment for thyroid eye disease, there weren't a lot of options. It's given me another tool in my tool chest.

Because of TEPEZZA, my conversations with my patients have changed for the better. I have a patient, and she gave me a picture of herself just before the thyroid eye disease started. And then she showed me a picture of her in the midst of the disease. And then she sent me a picture just a couple of weeks after her last infusion, and her proptosis had improved, her eyes weren’t bulging, she was really looking much more like herself again, and there she was, with her son, her grandchild and just beaming.

Each patient’s thyroid eye disease journey is different, but it’s really rewarding to be part of these patient’s lives. With TEPEZZA, I can help impact that journey.

 
IMPORTANT SAFETY INFORMATION
 
Warnings and Precautions
 

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD. If IBD exacerbation is suspected, discontinue use of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

 

Adverse Reactions
 

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, ear discomfort, weight decreased, nail disorders, and menstrual disorders.

Please see Full Prescribing Information or visit TEPEZZAhcp.com for more information.

Learn more about TEPEZZA at TEPEZZAhcp.com
TEPEZZA® (teprotumumab-trbw) TED Treatment | HCP Home

REFERENCES:

 

1. TEPEZZA (teprotumumab-trbw) [prescribing information] Amgen. 2. Douglas RS, Couch S, Wester ST, et al. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab. 2024;109(1):25-35. 3. Kahaly GJ, Petrak F, Hardt J, et al. Psychosocial morbidity of Graves’ orbitopathy. Clin Endocrinol (Oxf). 2005;63(4):395-402. 4. Estcourt S, Vaidya B, Quinn A, et al. The impact of thyroid eye disease upon patients’ wellbeing: a qualitative analysis. Clin Endocrinol (Oxf). 2008;68(4):635-639. 5. Smith TJ, Hegedüs L, Lesser I, et al. How patients experience thyroid eye disease. Front Endocrinol (Lausanne). 2023;14:1283374. 6. Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomized double-masked placebo-controlled multicenter trials. Lancet Diabetes Endocrinol. 2021;9(6):360-372. 7. Supplement to: Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomized double-masked placebo-controlled multicenter trials. Lancet Diabetes Endocrinol. 2021;9(6):360-372. 8. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748-1761. 9. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352. 10. Data on file, Amgen; 2025. 11. Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022;129(4):438-449.

TEPEZZA® (teprotumumab-trbw) TED Treatment | HCP Home